| Quarter | Score |
|---|---|
| 2022-Q1 | 49.4 |
| 2022-Q3 | 65.8 |
| 2022-Q4 | 49.5 |
| 2023-Q1 | 49.2 |
| 2023-Q2 | 63.6 |
| 2023-Q3 | 48.0 |
| 2023-Q4 | 53.2 |
| 2024-Q1 | 48.4 |
| 2024-Q2 | 46.9 |
| 2024-Q3 | 65.4 |
| 2024-Q4 | 85.9 |
| 2025-Q1 | 66.0 |
| 2025-Q2 | 70.5 |
| 2025-Q3 | 85.8 |
| 2025-Q4 | 85.9 |
| 2026-Q1 | 85.9 |
| 2026-Q2 | 86.0 |
Funds reducing exposure or consensus momentum fading
Trading +48.3% above funds' purchase price — elevated pullback risk
2 of 18 tracked funds hold HCC. Avg conviction: 21.7%. Net trimming. First tracked at $62.31 (current +48.3% vs tracked).
Pabrai Investment Funds has 43.3% in this stock
Benchmark comparison unavailable
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Pabrai Investment Funds | 43.3% | Reduce |
| Citadel Advisors | 0.0% | Reduce |